McKesson Corporation (NYSE:MCK) has been a model of consistent growth within the bio-tech sector, showing strong, long-term financial performance. The company has a robust institutional backing, with over 88% of MCK held by institutional owners. This investment profile has attracted the attention of financial giants such as Larry Robbins, expressing bullish sentiments on MCK stock. With a 306% gain for those who invested five years ago, McKesson is considered a strong investment. Furthermore, the company has shown positive responses to market fluctuations and outcompetes rivals on strong trading days. Notably, MCK witnessed stock increases even when the rest of the market declined. The corporation recently completed the divestiture of its Canada-based Rexall and Well.ca businesses. McKesson has displayed potential financial power, attracting more investors. On the contrary, MCK was down 15.2% in Q3, but investors' confidence remains unshaken. The firm released its second-quarter fiscal 2025 results, which successfully raised its full-year EPS guidance. Yet, some risks persist, including the impact of supply and demand issues for weight-loss drugs on revenue.
Mckesson Corporation MCK News Analytics from Wed, 07 Aug 2024 07:00:00 GMT to Sat, 25 Jan 2025 14:19:42 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor 6
